230 Chapter 10 62. Lee JE, Lee S, Park S, Lee SO, Lee SH. Impact of agr functionality on the outcome of patients with methicillin- susceptible Staphylococcus aureus bacteremia. Microbiol Spectr. 2021;9(1):e0011621. 63. Lee YW, Bae S, Yang E, et al. Clinical and microbiological characteristics of hospitalacquired methicillin- resistant Staphylococcus aureus bacteremia caused by a communityassociated PVL-negative strain. Open Forum Infect Dis. 2021;8(9):ofab424. 64. Lesens O, Brannigan E, Bergin C, Christmann D, Hansmann Y. Impact of the use of aminoglycosides in combination antibiotic therapy on septic shock and mortality due to Staphylococcus aureus bacteremia. Eur J Intern Med. 2006;17(4):276-280. 65. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin- intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis. 2009;199(5):619-624. 66. Melzer M, Welch C. Thirty-day mortality in UK patients with community-onset and hospital-acquired meticillin-susceptible Staphylococcus aureus bacteraemia. J Hosp Infect. 2013;84(2):143-150. 67. Meredith J, Onsrud J, Davidson L, et al. Successful use of telemedicine infectious diseases consultation with an antimicrobial stewardship-led Staphylococcus aureus bacteremia care bundle. Open Forum Infect Dis. 2021;8 (6):ofab229. 68. Mölkänen T, Ruotsalainen E, Rintala EM, Järvinen A. Predictive value of C-reactive protein (CRP) in identifying fatal outcome and deep infections in Staphylococcus aureus bacteremia. PLoS One. 2016;11(5):e0155644. 69. Murdoch F, Danial J, Morris AK, et al. The Scottish enhanced Staphylococcus aureus bacteraemia surveillance programme: the first 18 months of data in adults. J Hosp Infect. 2017;97(2):133-139. 70. Nambiar K, Seifert H, Rieg S, et al; International Staphylococcus aureus collaboration (ISAC) study group (with linked authorship to members in the Acknowledgements) and the ESCMID Study Group for Bloodstream Infections and Sepsis (ESGBIS). Survival following Staphylococcus aureus bloodstream infection: a prospective multinational cohort study assessing the impact of place of care. J Infect. 2018;77(6):516-525. 71. Osthoff M, Sidler JA, Lakatos B, et al. Low-dose acetylsalicylic acid treatment and impact on short-term mortality in Staphylococcus aureus bloodstream infection: a propensity score-matched cohort study. Crit Care Med. 2016;44(4):773-781. 72. Papadimitriou-Olivgeris M, Caruana G, Senn L, Guery B. Predictors of mortality of Staphylococcus aureus bacteremia among patients hospitalized in a Swiss university hospital and the role of early source control; a retrospective cohort study. Eur J Clin Microbiol Infect Dis. 2023;42(3):347-357. 73. Park KH, Chong YP, Kim SH, et al. Community-associated MRSA strain ST72-SCCmecIV causing bloodstream infections: clinical outcomes and bacterial virulence factors. J Antimicrob Chemother. 2015;70(4):1185-1192. 74. Paulsen J, Mehl A, Askim Å, Solligård E, Åsvold BO, Damås JK. Epidemiology and outcome of Staphylococcus aureus bloodstream infection and sepsis in a Norwegian county 19962011: an observational study. BMC Infect Dis. 2015;15(1):116. 75. Perovic O, Koornhof H, Black V, Moodley I, Duse A, Galpin J. Staphylococcus aureus bacteraemia at two academic hospitals in Johannesburg. S Afr Med J. 2006;96(8):714-717. 76. Rieg S, Jonas D, Kaasch AJ, et al. Microarray-based genotyping and clinical outcomes of Staphylococcus aureus bloodstream infection: an exploratory study. PLoS One. 2013;8(8):e71259.
RkJQdWJsaXNoZXIy MTk4NDMw